€1.47
3.54% today
Xetra, Nov 26, 12:42 pm CET
ISIN
DE000A1X3W00
Symbol
MDG1
Index
Sector
Industry

MediGene AG Stock price

€1.52
-0.31 16.90% 1M
-0.82 34.87% 6M
-1.37 47.38% YTD
-1.44 48.56% 1Y
-4.88 76.19% 3Y
-9.05 85.58% 5Y
-5.80 79.20% 10Y
Xetra, Closing price Mon, Nov 25 2024
-0.01 0.78%
ISIN
DE000A1X3W00
Symbol
MDG1
Index
Sector
Industry

Key metrics

Market capitalization €11.23m
Enterprise Value €1.03m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.14
P/S ratio (TTM) P/S ratio 1.51
P/B ratio (TTM) P/B ratio 1.14
Revenue growth (TTM) Revenue growth -17.51%
Revenue (TTM) Revenue €7.45m
EBIT (operating result TTM) EBIT €-15.75m
Free Cash Flow (TTM) Free Cash Flow €-14.49m
EPS (TTM) EPS €-1.23
P/E forward negative
P/S forward 1.02
EV/Sales forward 0.09
Show more

Is MediGene AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MediGene AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MediGene AG:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MediGene AG:

Buy
100%

Financial data from MediGene AG

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
7.45 7.45
17% 17%
100%
- Direct Costs 2.68 2.68
88% 88%
36%
4.77 4.77
134% 134%
64%
- Selling and Administrative Expenses 6.77 6.77
149% 149%
91%
- Research and Development Expense 12 12
37% 37%
164%
-14 -14
53% 53%
-191%
- Depreciation and Amortization 1.50 1.50
93% 93%
20%
EBIT (Operating Income) EBIT -16 -16
49% 49%
-211%
Net Profit -16 -16
45% 45%
-214%

In millions EUR.

Don't miss a Thing! We will send you all news about MediGene AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediGene AG Stock News

Company Profile

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.

Head office Germany
CEO Selwyn Ho
Employees 86
Founded 1994
Website www.medigene.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today